Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268448 · ClinicalTrials.gov registry record · Phase 1
Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02268448: Completed Phase 1 study, sponsored by University of Minnesota.
NCT02268448 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02268448, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of oral clonidine in subjects with symptomatic atopic dermatitis and to assess the safety and efficacy of oral naltrexone in subjects with symptomatic atopic dermatitis.
Primary Outcome
Participants will take personal surveys regarding the reduction in itching after 3 months
Interventions
- DRUG Naltrexone
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-07 |
| Est. Completion | 2022-09 |
| Phase | Phase 1 |
What the finished NCT02268448 record still lists
NCT02268448 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Naltrexone is the first listed.
NCT02268448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02268448 about?
NCT02268448 is a clinical study titled "Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function". The purpose of this study is to assess the safety and efficacy of oral clonidine in subjects with symptomatic atopic dermatitis and to assess the safety and efficacy of oral naltrexone in subjects with symptomatic atopic dermatitis.
What is the current status of trial NCT02268448?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-07. Estimated completion is 2022-09.
What interventions are being tested in trial NCT02268448?
The interventions under investigation include: Naltrexone (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT02268448?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02268448's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia